Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gabapentin and gabapentin + montelukast for cough in hospitalized COVID-19 patients
IRCT20150721023282N24Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of gabapentin, montelukast and dextromethorphan in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: cough severity. Started Jun 2022; status: completed.
02
Drugs
gabapentinmontelukastdextromethorphan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20150721023282N24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150721023282N24.